Skip to main content
OpenTrials
Completed

NCT Number: NCT01625143

Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia

This laboratory study is looking into genes in samples from younger patients with relapsed acute lymphoblastic leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

B-cell Childhood Acute Lymphoblastic Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Precursor Cell Lymphoblastic Leukemia-Lymphoma Recurrent Childhood Acute Lymphoblastic Leukemia Untreated Childhood Acute Lymphoblastic Leukemia

Age range

Up to 21 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Children's Oncology Group

Arcadia, California, 91006-3776, United States

About this study

OBJECTIVES:

I. To identify global changes in the epigenome and various underlying histone modifications that characterize relapsed acute lymphoblastic leukemia (ALL).

II. To identify specific transcription factor-binding sites associated with histone alterations.

III. To correlate gene expression changes of differentially regulated genes at relapse with underlying chromatin modifications.

OUTLINE:

Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of B-cell acute lymphoblastic leukemia
  • Paired diagnosis-relapse primary patient samples obtained from the Children's Oncology Group (COG) cell bank

Treatment and study plan

laboratory biomarker analysis

Other

Correlative studies

Primary outcomes

  1. Cellular origins of relapse and the underlying epigenetic mechanisms associated with drug resistance

    Time frame: 1 month

  2. Genes associated with histone modification

    Time frame: 1 month

  3. Biological pathways involved in relapse

    Time frame: 1 month

Sponsors and collaborators

Lead sponsor

Children's Oncology Group

Network

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Molecular Taxonomy of Pediatric Cancer

Important dates

Study start
2012
Primary completion
2016
First posted
Jun 21, 2012
Registry last updated
May 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.